Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma-Reference-Cited by-同舟云学术

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Published:2016-04-25 Issue:8 Volume:76 Page:853-867
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Moreau Philippe,van de Donk Niels W. C. J.,Miguel Jesus San,Lokhorst Henk,Nahi Hareth,Ben-Yehuda Dina,Cavo Michele,Cook Gordon,Delforge Michel,Einsele Hermann,Zweegman Sonja,Ludwig Heinz,Driessen Christoph,Palumbo Antonio,Facon Thierry,Plesner Torben,Dimopoulos Meletios,Sondergeld Pia,Sonneveld Pieter,Mateos María-Victoria

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-016-0573-4.pdf

Reference67 articles.

1. Grillo-López AJ, White CA, Dallaire BK, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol. 2000;1(1):1–9.

2. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027–33.

3. Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, et al. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am J Hematol. 2015;90(11):981–5.

4. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia. 2012;26:149–57.

5. Laubach JP, Tai YT, Richardson PG, Anderson KC. Daratumumab granted breakthrough drug status. Expert Opin Investig Drugs. 2014;23(4):445–52.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis;Hematology;2024-09-09

2. Addressing hypersensitivity reactions induced by Daratumumab: A review of management approaches and preventive measures;Indian Journal of Pathology and Oncology;2023-09-15

3. Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?;International Journal of Molecular Sciences;2022-12-14

4. Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma;Journal of Oncology Pharmacy Practice;2022-06-20

5. Daratumumab: A review of current indications and future directions;Seminars in Oncology;2022-02